The Board of Synmosa resolves to
increase capital stock by earnings recapitalization
Date of events
2022/03/29
To which item it meets
paragraph 11
Statement
1.Date of the board of directors resolution:2022/03/29
2.Source of capital increase funds:profit for fiscal 2021
3.Whether to adopt shelf registration
(Yes, please state issuance period/No):No
4.Total monetary value of the issuance and number of shares issued (shares
issued not including those distributed to employees if consisting in
capital increase from earnings or capital surplus):
30,016,520 shares，AMOUT NTD 300,165,200
5.If adopting shelf registration, monetary value and number of shares
to be issued this time:Not applicable
6.The remaining monetary value and shares after this issuance when
adopting shelf registration:Not applicable
7.Par value per share:NTD $10
8.Issue price:Not applicable
9.Number of shares subscribed for by or allocated to employees:
Not applicable
10.Number of shares publicly sold:Not applicable
11.Ratio of shares subscribed by or allotted as stock
dividends to existing shareholders:
100 share distributed gratis per 1,000 share
12.Handling method for fractional shares and shares
unsubscripted for by the deadline:
If the stock dividends include any fractional shares which are
less than one full share, the shareholders of two or more may
arrange for pooling together of their fractional shares to form
one full share and register the same under the name of one of the
shareholders within 5 days after the ex-rights date. For the
fractional shares which cannot be pooled within the specified period,
such remainder will be subscribed by designated individuals arranged
by the Chairman .
13.Rights and obligations of these newly issued shares:
The same as the issued and existing shares.
14.Utilization of the funds from the capital increase:
Not applicable
15.Any other matters that need to be specified:
(1)If the outstanding shares changed result in the
distributing ratio of stock dividends changed,
the final ratio will be determined fully by the Board authorized
by Shareholders'Meeting.
(2)If the plan of increasing capital stock is changed by the
authorities, it is determined fully to chang by the Board as
authorized by the Shareholders' Meeting.
(3)The ex-rights date will be determined fully by the Board as
authorized by the Shareholders' Meeting after the capital stock
increase is approved by the authorities.
Attachments
Original Link
Original Document
Permalink
Disclaimer
Synmosa Biopharma Corporation published this content on 29 March 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 29 March 2022 07:43:02 UTC.
SYNMOSA BIOPHARMA CORPORATION is a Taiwan-based company principally engaged in the manufacture and sales of various kinds of pharmaceuticals and medical equipment. The Company's main products include respiratory drugs, cardiovascular and urinary drugs, gastrointestinal drugs, hormones, anti-tumor drugs, antibiotics and health products. The Company is also involved in the manufacture and sales of various kinds of cosmetics and animal medicines, as well as various kinds of chemical food additives and beverages. The Company distributes its products in domestic market and to overseas markets.
SYNMOSA BIOPHARMA CORPORATION 
